Since 2DG has been shown to impact TRAIL’s cognate receptor expression (DR) in vitro, and both of these drugs are well characterized and proven safe in clinical trials, we sought to determine if 2DG treatment could sensitize TRAIL-resistant human colon cancers to TRAIL-induced apoptosis. This evidence concerns the gene TNFSF10 and malignant colon neoplasm.